

Table 1. Demographic data of the study group

Value	Item	
33.97±9.72	Mean±SD	Age (years)
30.5(20-60)	Median(range)	
21(70%)	Male	Sex
9(30%)	Female	
7(23.3%)	Single	Marital status
22(73.3%)	Married	
1(3.3%)	Widow	
8(26.7%)	Housewife	Occupation
2(6.7%)	Not working	
15(50%)	Worker	
3(10%)	Driver	
2(6.7%)	Accountant	
10(33.3%)	Urban	Residence
20(66.7%)	Rural	
3(10%)	Good	Socioeconomic status
27(90%)	Low	
13(43.3%)	Yes	Smoking / addiction
17(56.7%)	No	

Table 2. Disease history

Value (yrs)	Item	
28.8±9.85	Mean±SD	Age at diagnosis
26.5(15-59)	Median(range)	
5.17±4.08	Mean±SD	Disease duration
4(0-20)	Median(range)	
11(36.7%)	Oral ulcer	First organ/system affected
10(33.3%)	Ocular manifestations	
3(10%)	CNS	
2(6.7%)	Articular	
2(6.7%)	Vascular lesion	
1(3.3%)	Genital ulcer	
1(3.3%)	Skin	

Table 3

Value	Genital ulcer analysis		Value	Oral ulcer analysis	
25(83.3%)	Present	Present or not	29(96.7%)	Present	Present or not
5(16.7%)	Absent		1(3.3%)	Absent	
23(92%)	Recurrent	De novo or recurrent	29(100%)	Recurrent	De novo or recurrent
2(8%)	De novo		17(58.6%)	Acute	
13(52%)	Acute	Onset	12(41.4%)	Insidious	Course
12(48%)	Insidious		29(100%)	Progressive	
25(100%)	Progressive	Course	24(82.8%)	Rounded	Shape
18(72%)	Rounded		5(17.2%)	Oval	
7(28%)	Oval	Shape	29(100%)	Painful	Painful or not
25(100%)	Painful		4(13.8%)	Lips only	
17(68%)	Scrotum	Site	14(48.3%)	Lips and gums	Site
3(12%)	Vulva		4(13.8%)	Lips and tongue	
5(20%)	Vaginal		1(3.3%)	Gums and	

	mucosa			tongue	
22(88%)	Present	Scars	1(3.3%)	Tongue only	
3(12%)	Absent		5(17.2%)	Buccal cavity	
23(92%)	One	Number	29(100%)	Present	Scars Number
1(4%)	Two		1(3.4%)	Two	
1(4%)	Many		3(10.3%)	Three	
			25(86.2%)	More than three	
Value	GIT manifestations		Value	Cutaneous manifestations	
4(13.3%)	Present	Present or not	13(43.3%)	Present	Present or not
26(86.7%)	Absent		17(56.7%)	Absent	
1(25%)	Gastritis	Type	6(46.2%)	Acniform nodules	Type
1(25%)	Peptic ulcer		4(30.8%)	Erythema nodosum	
1(25%)	Constipation		2(15.3%)	Acniform nodules & erythema nodosum	
1(25%)	Diarrhea		1(7.7%)	Pseudo-folliculitis	
Value	Articular manifestations		Value	Ocular manifestations	
18(60%)	Present	Present or not	22(73.3%)	Present	Present or not
12(40%)	Absent		8(26.7%)	Absent	
2(11.1%)	Ankles	Site	6(27.3%)	Anterior uveitis	Type
1(5.6%)	Hand, wrist, knee and ankle		5(22.7%)	Posterior uveitis	
1(5.6%)	Hand, wrist, knee, ankle, shoulder, elbow		7(31.8%)	Panuveitis	
1(5.6%)	Knee and ankle		1(4.5%)	Panuveitis ended with complete blindness	
1(5.6%)	Knee and wrist		1(4.5%)	Blurring and posterior uveitis	
7(38.9%)	Knees		1(4.5%)	Hemi-retinal vascular occlusion	
1(5.6%)	Plantar fasciitis		1(4.5%)	Intraocular hypertension and posterior uveitis	
1(5.6%)	Wrist and ankle				
Value	Articular manifestations		Value	CNS manifestations	
3(16.7%)	Wrist, elbow, knee, and ankle	Duration (months)	6(20%)	Present	Present or not
26.2±22.3	Mean±SD		24(80%)	Absent	
24(1-72)	Median(range)	De novo or recurrent	4(66.7%)	Headache	Type
5(27.8%)	De novo		1(16.7%)	Transverse myelitis	

13(72.2%)	Recurrent	Onset	1(16.7%)	Quadri paresis	Vascular manifestations Present or not
4(22.2%)	Acute		Value	Present	
14(77.8%)	Insidious		9(30%)	Absent	
			21(70%)	Absent	Type
			4(44.4%)	DVT (de novo)	
			2(22.2%)	DVT (recurrent)	
			2(22.2%)	Thrombosis	
			1(11.1%)	Vasculitis	

Table 4. Other chronic diseases

%	No	Disease
0	0	Diabetes mellitus
6.7%	2	Hypertension
3.3%	1	Malar rash
3.3%	1	Hair falling
3.3%	1	Facial palsy
3.3%	1	Previous myocardial infarction
3.3%	1	HCV infection
3.3%	1	Ecchymotic patches in abdomen & dyspnea grade III & Rt Cataract & tonsilectomy

Table 5. Other diseases in Relatives

%	No	Item
93.3%	28	No
3.3%	1	Behcet's disease in 2 nd -degree relative
3.3%	1	Rheumatoid arthritis in 2 nd -degree relative

Table 6. Examination

Value	Item	
5(16.7%)	Positive	Pathergy test
25(83.3%)	Negative	
4(13.3%)	4	Behcet's disease scoring
9(30%)	5	
4(13.3%)	6	
8(26.7%)	7	
5(16.7%)	8	
6.03±1.35	Mean±SD	
6(4-8)	Median(range)	

Table 7. Therapy has taken

%	No	Drug
93.3%	28	Azathioprine
50%	15	Hydroxychloroquine
26.7%	8	Cyclosohphamide
13.3%	4	Methotrexate
70%	21	Colchicine
86.7%	26	Steroids (prednisolone)
73.3%	22	Oracle gel
46.7%	14	Calcium supplementation
53.3%	16	Bone one
3.3%	1	Tetracycline
3.3%	1	Trental
10%	3	Proton pump inhibitors
6.7%	2	Artificial eye drops
3.3%	1	Potassium permanganate
3.3%	1	Antibiotics (claforan)